RedHill Biopharma and South Korea’s Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
RedHill received the first tranche of $5 million in a private placement of restricted stock priced at $6.04 per ADS, representing a 20% premium based on the 30 trading days’ volume weighted average price (VWAP) ending on the effective date RedHill granted Kukbo a right of first offer for opaganib, RHB-107 (upamostat) and Talicia® for South Korea […]
